The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Treatment-related microangiopathic glomerulopathy and severe chronic kidney disease (CKD) in recurrent epithelial ovarian cancer (rEOC): A possible relationship with pegylated liposomal doxorubicin (PLD).
M. Kwa
No relevant relationships to disclose
R. A. Baumgartner
No relevant relationships to disclose
L. Shavit
No relevant relationships to disclose
I. Barash
No relevant relationships to disclose
J. Michael
No relevant relationships to disclose
I. Puzanov
No relevant relationships to disclose
J. Kopolovic
No relevant relationships to disclose
O. Rosengarten
No relevant relationships to disclose
A. Hung
No relevant relationships to disclose
H. Jones
No relevant relationships to disclose
A. Gabizon
Honoraria - Johnson & Johnson
F. Muggia
Consultant or Advisory Role - Johnson & Johnson